Literature DB >> 26613638

An observational study of clozapine induced sedation and its pharmacological management.

Sònia Ramos Perdigués1, Rosa Sauras Quecuti2, Anna Mané3, Louisa Mann4, Clare Mundell4, Emilio Fernandez-Egea5.   

Abstract

Clozapine induced sedation is common but its management is unclear. We analyzed the factors associated with clozapine-induced sedation and the efficacy of common pharmacological strategies. We conducted a naturalistic observational study using two years electronic records of a cohort patients and three analyses: a cross sectional analysis of factors associated with total number of hours slept (as an objective proxy of sedation), and two prospective analyses of which factors were associated with changes in hours slept and the efficacy of two pharmacological strategies. 133 patients were included, of which 64.7% slept at least 9h daily. Among monotherapy patients (n=30), only norclozapine levels (r=.367, p=.03) correlated with hours slept. Using the prospective cohort (n=107), 42 patients decreased the number of hours slept, due to decreasing clozapine (40%) or augmenting with aripiprazole (36%). These two strategies were recommended to 22 (20.6%) and 23 (21.5%) subjects respectively but the majority (81.8% and 73.9%) did not reduce number of hours slept. Thus, pharmacological and non-pharmacological factors are involved in sedation. Norclozapine plasma levels correlated with total sleeping hours. Reducing clozapine and aripiprazole augmentation were associated to amelioration of sedation, although both strategies were effective only in a limited numbers of subjects.
Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Clozapine; Drowsiness; Management; Schizophrenia; Sedation; Treatment

Mesh:

Substances:

Year:  2015        PMID: 26613638     DOI: 10.1016/j.euroneuro.2015.11.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital.

Authors:  Wenying Yi; Shenglin She; Jie Zhang; Haibo Wu; Yingjun Zheng; Yuping Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2020-11-24       Impact factor: 2.570

3.  Excessive sleepiness in patients with psychosis: An initial investigation.

Authors:  Sarah Reeve; Bryony Sheaves; Daniel Freeman
Journal:  PLoS One       Date:  2021-01-15       Impact factor: 3.240

4.  Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia.

Authors:  Emilio Fernandez-Egea; Yulia Worbe; Miguel Bernardo; Trevor W Robbins
Journal:  Psychol Med       Date:  2018-02-19       Impact factor: 7.723

5.  Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study.

Authors:  Nobuyuki Nomura; Kohei Kitagawa; Ryuhei So; Fuminari Misawa; Masafumi Kodama; Hiroyoshi Takeuchi; Robert Bies; Thomas Straubinger; Christopher Banker; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.